1027972-80-0Relevant articles and documents
Peptidomimetic inhibitors of the human cytomegalovirus protease
Ogilvie, William,Bailey, Murray,Poupart, Marc-André,Abraham, Abraham,Bhavsar, Amit,Bonneau, Pierre,Bordeleau, Josée,Bousquet, Yves,Chabot, Catherine,Duceppe, Jean-Simon,Fazal, Gulrez,Goulet, Sylvie,Grand-Ma?tre, Chantal,Guse, Ingrid,Halmos, Ted,Lavallée, Pierre,Leach, Michael,Malenfant, Eric,O'Meara, Jeff,Plante, Raymond,Plouffe, Céline,Poirier, Martin,Soucy, Fran?ois,Yoakim, Christiane,Déziel, Robert
, p. 4113 - 4135 (2007/10/03)
The development of peptidomimetic inhibitors of the human cytomegalovirus (HCMV) protease showing sub-micromolar potency in an enzymatic assay is described. Selective substitution of the amino acid residues of these inhibitors led to the identification of tripeptide inhibitors showing improvements in inhibitor potency of 27-fold relative to inhibitor 39 based upon the natural tetrapeptide sequence. Small side chains at P1 were well tolerated by this enzyme, a fact consistent with previous observations. The S2 binding pocket of HCMV protease was very permissive, tolerating lipophilic and basic residues. The substitutions tried at P3 indicated that a small increase in inhibitor potency could be realized by the substitution of a tert-leucine residue for valine. Substitutions of the N- terminal capping group did not significantly affect inhibitor potency. Pentafluoroethyl ketones, α,α-difluoro-β-keto amides, phosphonates and α- keto amides were all effective substitutions for the activated carbonyl component and gave inhibitors which were selective for HCMV protease. A slight increase in potency was observed by lengthening the P1' residue of the α-keto amide series of inhibitors. This position also tolerated a variety of groups making this a potential site for future modifications which could modulate the physicochemical properties of these molecules.
